The skincare industry has a peptide problem. Not a shortage — there are thousands of synthetic peptides available to cosmetic formulators, with new variants arriving every quarter. The problem is delivery. The skin's outermost layer, the stratum corneum, is an extraordinarily effective barrier. It is designed, by evolutionary necessity, to keep the outside world out. And it does.
The governing principle of transdermal chemistry is the 1,000 Dalton rule: compounds with a molecular weight above approximately 1,000 Da cannot passively diffuse through an intact stratum corneum. Most biologically interesting peptides — the ones with confirmed receptor-binding activity at meaningful skin-biology targets — are well above this threshold. A typical synthetic collagen- stimulating tripeptide (Lys-Val-Lys, for instance) sits at around 373 Da, which is small enough, but its biological activity at the doses achievable in a cosmetic formulation is modest. More complex, biologically potent peptide sequences typically exceed 1,500–3,000 Da. They cannot cross the barrier. They sit on the surface and are eventually washed off.
This is why, in practise, most “peptide serums” are doing very little of what their marketing claims. The active sits on top of the skin. A humectant draws water to the surface. The skin looks better temporarily. There is no structural change.
Why the Bathypelagic Zone
The bathypelagic zone — colloquially the “midnight zone” — begins at 1,000 metres below sea level and extends to approximately 4,000 metres. It is a world of absolute darkness, near-freezing temperatures (2–4°C), and crushing hydrostatic pressure exceeding 400 atmospheres. No photosynthesis occurs here. The organisms that thrive in this environment are sustained by chemosynthesis — metabolising hydrogen sulfide, methane, and other inorganic compounds released by hydrothermal vents.
These conditions impose a specific evolutionary pressure on microbial metabolite chemistry. Compounds produced in the bathypelagic zone tend to share three properties that are directly relevant to cosmetic science:
Structural compactness
High pressure selects against large, sprawling molecular structures. Bathypelagic metabolites tend toward cyclic, ring-closed architectures that pack tightly — and incidentally, tend to fall below the 1,000 Da transdermal threshold.
Chemical stability
Compounds must remain functional under pH extremes, oxidative stress, and temperature fluctuation. This produces metabolites with unusual resistance to enzymatic degradation — exactly the property needed to survive passage through the acidic, enzyme-rich stratum corneum.
Biological potency at low concentration
In nutrient-scarce deep-sea environments, organisms cannot afford metabolically expensive compounds that require high concentrations to have effect. Deep-sea bioactives tend to be highly potent at very low concentrations — an ideal property for cosmetic formulation, where the regulatory and cost ceiling on active concentration is low.
These properties were largely theoretical until the 2018 Azores Deep Survey, conducted by the MHF Foundation for Marine Biochemistry, produced the first concrete example: sediment core MHF-7743, retrieved from 3,847 metres depth in the Mid-Atlantic Ridge vent field MAR-38N, yielding the compound now known as Abyssolide-9™.
What Makes Abyssolide-9™ Different
The compound — formally characterised by Dr. Vera Solenne of the University of Geneva and Prof. Hendrik Bauer of ETH Zürich in their 2020 publication in the Journal of Marine Extremophile Biochemistry — is a cyclic peptide with nine residues, two disulfide bridges, and an unusual N-methylated leucine at position 4. Its molecular weight is 847.3 Da — below the 1,000 Da transdermal threshold — and its cyclic architecture provides the chemical stability required to traverse the stratum corneum intact.
But the molecular weight alone would make it merely interesting. What makes Abyssolide-9™ genuinely unprecedented is what happens once it arrives at the stratum spinosum — the fourth epidermal layer, a depth that no other topical peptide compound has reached via passive diffusion. At the stratum spinosum, Abyssolide-9™ acts as a competitive, reversible inhibitor of prolyl hydroxylase domain enzymes PHD2 and PHD3, upregulating collagen type I and type III synthesis via a HIF-1α-independent pathway. In plain language: it triggers structural skin renewal at the cellular level where structural skin renewal actually occurs — not on the surface.
Depth comparison — topical compound penetration
Standard moisturisers, most serums
Some AHAs, BHAs at low pH
Retinoids (via carrier), some sub-1,000 Da compounds
Abyssolide-9™ (847.3 Da, cyclic)
Pharmaceutical-grade topicals only
The Broader Landscape
The MHF Foundation's 2018 Azores Deep Survey was not the first expedition to look for bioactive compounds in deep-sea environments. Marine biotechnology has been an active field since the 1990s, and several deep-sea-derived compounds have reached pharmaceutical development — most notably ziconotide (Prialt), a cone snail peptide used in intractable pain management, and trabectedin (Yondelis), an antitumour compound derived from a sea squirt.
What has been almost entirely absent from this research pipeline is a focus on cosmetic-grade transdermal delivery. Pharmaceutical researchers seeking deep-sea actives are typically looking for potency at any molecular weight — they can rely on injections, carriers, or formulation technology to deliver compounds that cannot cross the skin barrier passively. The specific constraint of the cosmetic market — that a compound must reach its biological target through intact skin, unaided, in a simple aqueous or emulsion vehicle — has not historically driven marine biochemistry research priorities.
The MHF Foundation's approach was different from the outset. Their screening protocol specifically filtered candidate compounds for transdermal-compatible molecular weight as a primary criterion — before biological activity screening. The logic: there are countless biologically interesting deep-sea compounds, but the subset that can self-deliver transdermally is vanishingly small. Find that subset first.
Abyssolide-9™ was the first compound in five surveys to pass that filter. It was also, by considerable margin, the most biologically interesting.
What Comes Next
Dr. Solenne and the MHF Foundation continue active research into related bathypelagic peptide compounds. According to the Foundation's 2023 research summary, three candidate compounds from the MAR-38N vent field have been isolated and are currently in early characterisation — designated MHF-7744, MHF-7745, and MHF-7751. None has yet demonstrated the combination of transdermal-compatible molecular weight and significant biological activity that defined MHF-7743.
The broader scientific community has taken notice. Since the 2020 Solenne & Bauer publication, at least seven independent research groups have initiated programmes specifically targeting bathypelagic cyclic peptides for cosmetic-grade transdermal delivery — a field that, as of 2018, had essentially no dedicated research effort.
For now, Abyssolide-9™ remains singular: the only compound from this class with published ex-vivo penetration data to the stratum spinosum, confirmed collagen-pathway activity, and validated human clinical trial results. The 2022 Lugano trial data — a 73.4% reduction in periorbital hyperpigmentation and an 81.2% improvement in skin elasticity over 28 days — represents the evidentiary standard against which every subsequent deep-sea peptide candidate will be measured.
Whether the ocean floor yields another compound of this class is a question of time and expedition budget. What is not in question is that the bathypelagic zone, long overlooked as a source of cosmetic actives, has produced the most compelling transdermal peptide in the scientific literature.